Selventa, Inc.

Other

Parabilis Medicines, Inc.

Philip Morris Products S.a.

Ty Matthew Thomson

Dexter Roydon Pratt

Dmitry Vasilyev

William M Ladd

David Drubin

Gregory Lawrence Verdine

Florian Martin

John Hanney McGee

Sebastian Christof Theodor Wahl

Raheleh Rezaei Araghi

Brian Frushour

Yue-Mei Zhang

Mark Joseph Mulvihill

The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.

Collections of peptides, peptide agents, and methods of use thereof

Disclosed herein are system, method, and computer program product embodiments for determining a score for a degree of activation of a biological network. An embodiment constructs a tree graph comprising a root node and a set of child nodes. The root node represents a biological network having a reference node and causal connections among a set of nodes that represent biological entities, biological processes, or other biological networks. Each child node represents a particular node in the biological network and is connected to the root node by a signed, directed edge pointing from the root node to that child node. Each child node also has an associated weight based on one or more paths connecting the child node to the reference node in the biological network. The embodiment further scores the tree graph based on scores assigned to the child nodes and the signs of the singed, directed edges.

Quantitative assessment of biological impact by scoring directed tree graphs of causally inconsistent biological networks

Scores for particular network models (those having a source node connected to a set of measurable downstream nodes via causal edges) are computed across multiple networks by accounting for an overlap between these models in a manner that reduces cross-network redundancy and increases the specificity of the network models for the network in which they are found. According to another aspect, a meta-network model is created for networks by accounting for the occurrence of network models that are found in multiple networks in a manner that reduces the redundancy across networks and that increases the specificity of the network model score. Preferably, this process provides additional weighting factors for each node in the network model.

Quantitative assessment of biological impact using overlap methods

A 'Specificity' statistic (or metric) is computed as a means to identify amplitude scores associated with a signature that can be attributed with high probability to a specific biological entity or process represented by the signature. Preferably, Specificity is computed by assessing a likelihood of a given null hypothesis, namely, that an amplitude score is not representative of the specific signature but, instead, is representative of a general trend in the applicable data set that can be measured by any signature that is comparable to the signature of interest. In a typical implementation, a first step to compute the Specificity metric is to construct a set of comparable signatures. Next, an amplitude score is computed for each of these signatures, preferably using the same data set. Then, the Specificity metric is computed, preferably as a two-tailed p-value, by placing the amplitude score for the signature of interest on a distribution of scores for the comparable signatures. Scores that have Specificity p-values less than a particular value, e.g., 0.05, are considered to be scores that can be attributed with high confidence to the signature of interest.

Determining whether a measurement signature is specific to a biological process

To directly compare two or more network perturbation amplitude scores and identify whether the difference between them is meaningful, an Uncertainty (confidence interval) for each of the scores is computed. According to this disclosure, experimental replicates of the measurements are used to compute the score Uncertainty, based on an assumption that variability between measurement replicates represents a largest source of error in the score. Preferably, at least three (3) experimental replicates for both treated and control conditions are used to compute Uncertainty.

Determining a confidence of a measurement signature score

One or more measurement signatures are derived from a knowledge base of casual biological facts, where a signature is a collection of measured node entities and their expected directions of change with respect to a reference node. The knowledge base may be a directed network of experimentally-observed casual relationships among biological entities and processes, and a reference node represents a perturbation. A degree of activation of a signature is then assessed by scoring one or more 'differential' data sets against the signature to compute an amplitude score. The amplitude score quantifies fold-changes of measurements in the signature. In one particular embodiment, the amplitude score is a weighted average of adjusted log-fold changes of measured node entities in the signature, wherein an adjustment applied to the log-fold changes is based on their expected direction of change. In an alternative embodiment, the amplitude score is based on quantity effects.

Growing community of inventors

Arlington, MA, United States of America

Ty Matthew Thomson